Table 2.

Expression of LAG-3 by tumor-infiltrating lymphocytes in malignant HL lymph nodes

Case no.Disease statusAge at diagnosis, y/sexHistologyLAG-3+ cells in HRS-positive regions*EBV tissue status
2 ND 45/F MC +++ Negative
8 ND 30/F NS ++ Negative
18 RL 44/M NS ++ Negative
22 Remission 48/M NS - Negative
28 ND 21/F NS + Negative
31 ND 76/M NS ++ Negative
32 ND 30/M NS ++ Positive
33 ND 26/M NS + Negative
35 ND 48/F NS ++ Positive
36 RL 34/F NS - Positive
38 Remission 33/M NS - Positive
40 ND 25/M NS + Positive
44 ND 22/F NS + Positive
47 ND 29/M MC ++ Negative
48 Remission 35/F MC +++ Positive
49 ND 45/F MC ++ Negative
50 Remission 21/M NS + Negative
51 RL 25/F NS - Negative
53 ND 22/M MC ++ Positive
54 Remission 24/F NS - Negative
55 Remission 42/M NLP + Negative
56 ND 20/M MC +++ Positive
57 ND 21/F MC +++ Positive
64 ND 43/M NS ++ Positive
65 RL 56/M NS + Negative
67 ND 13/F MC +++ Positive
69 RL 34/F NS + Negative
70 ND 24/M NS ++ Negative
71 RL 31/F NS + Negative
72 ND 26/M NS - Negative
74 ND 34/M NS ++ Negative
76 ND 23/M NS + Negative
77 ND 36/M NS ++ Negative
78 ND 21/M NS - Negative
79 ND 26/M NS +++ Positive
80 ND 34/M LR +++ Negative
81 ND 28/M NS ++ Positive
82 ND 36/F NS ++ Negative
83 ND 29/F NS ++ Negative
84 ND 23/F NS ++ Positive
85 ND 59/M NS +++ Negative
86 ND 20/M NLP ++ Negative
88 ND 19/F NS - Negative
  • There was a significant correlation between percent LAG-3 staining and MC and/or LR histology versus NS (r = 0.555, P < .001) and between LAG-3 and positive EBV status (r = 0.31, P = .036).

    ND indicates newly diagnosed; MC, mixed cellularity; NS, nodular sclerosing); RL, relapsed; Remission, long-term remission; NLP, nodular lymphocyte predominant; and LR, lymphocyte rich.

  • * Percentage of non-HRS cells within HRS-rich areas that are positive for LAG-3; +++ indicates 74% to 50%; ++, 49% to 25%; +, 24% to 10%; -, less than 10%.